相关实验视频

Updated: Jan 11, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

在胃瘤中向MUC17的CAR-T细胞疗法

Sangwoo Park^1,2,3, Cassidy E Ho^1,3, Filippo Birocchi^1,2,3

¹Krantz Family Center for Cancer Research and Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA.

Journal for immunotherapy of cancer

|November 18, 2025

概括

化学抗原受体 (CAR) -T细胞疗法通过向MUC17抗原,对胃癌显示有前途. 在临床前模型中,MUC17特定的CAR-T细胞有效地抑制了瘤生长,毒性最小.

科学领域:

免疫治疗是一种免疫疗法.
在瘤学瘤学.
细胞疗法细胞疗法

背景情况:

卡特-T细胞疗法在血液癌症中有效,但由于抗原识别挑战,在固体瘤中受到限制.
识别瘤特异性抗原,可替代正常组织,对于固体瘤CAR-T疗效至关重要.

研究的目的:

评估MUC17作为一种新的向抗原,用于胃癌中CAR-T细胞治疗.
开发和验证MUC17特异性CAR-T细胞用于固体瘤治疗.

主要方法:

确定了MUC17作为具有低正常组织表达和高胃癌上调高的向抗原.
开发出MUC17特定的CAR-T细胞,具有4-1BB/CD3ζ信号域.
评估了体外细胞毒性,细胞因子释放和T细胞表型;在NSG异种移植模型中评估了体内疗效.

主要成果:

MUC17 CAR-T细胞表现出强大的抗原特异性杀死胃癌细胞.
CAR-T细胞表现出强大的细胞因子分泌和持续的效应器功能,具有中央记忆表型.
在体内研究表明,在胃癌模型中显著抑制瘤生长,没有观察到毒性.

结论:

MUC17是胃癌的一个有前途的免疫治疗点.
针对像MUC17这样的细胞表面糖蛋白,扩大了固体瘤中潜在的CAR-T标.
这种方法增强了CAR-T细胞疗法的适用性,用于挑战固体恶性瘤.

关键词:

化学抗原受体 - - CAR 胃癌胃癌胃癌胃癌免疫治疗是一种免疫疗法.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.